等待開盤 12-13 09:30:00 美东时间
+0.230
+0.93%
今日重点评级关注:摩根士丹利:维持Kyverna Therapeutics"超配"评级,目标价从20美元升至25美元;Maxim Group:维持Capricor Therapeutics"买入"评级,目标价从25美元升至50美元
12-05 08:35
Stephens & Co. analyst Jeff Garro reiterates Privia Health Gr (NASDAQ:PRVA) with a Overweight and maintains $32 price target.
12-04 22:16
今日重点评级关注:HC Wainwright & Co.:维持PDS Biotechnology"买入"评级,目标价从13美元升至15美元;HC Wainwright & Co.:维持PepGen Inc."买入"评级,目标价从18美元升至20美元
11-14 10:43
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
11-13 09:58
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
11-11 10:49
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 10:22
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
11-07 23:20
Citizens analyst Constantine Davides maintains Privia Health Gr (NASDAQ:PRVA) with a Market Outperform and raises the price target from $30 to $31.
11-07 22:11
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12